File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Treatment of acromegaly with bromocriptine

TitleTreatment of acromegaly with bromocriptine
Authors
Issue Date1979
PublisherBlackwell Publishing Asia. The Journal's web site is located at http://www.blackwellpublishing.com/journals/IMJ
Citation
Australian And New Zealand Journal Of Medicine, 1979, v. 9 n. 3, p. 225-232 How to Cite?
AbstractFive men and three women with active acromegaly were treated with bromocriptine. After three months' therapy (30 mg/day) mean GH during the day decreased by 50% in six out of eight subjects. In the remaining two subjects (non-responders) GH was persistently over 100 μg/l. Mean GH during glucose tolerance test were not significantly decreased in three out of the eight subjects, of whom two were the non-responders. The minimum dose of bromocriptine required to achieve maximum GH suppression ranged from 7.5 to 20 mg/day. In contrast, serum prolactin (PRL) throughout the day suppressed significantly in all subjects after 5 mg/day bromocriptine. Decreases in clinical symptoms, hand volume, urinary hydroxyproline and calcium excretion were seen in about half of the subjects. Three of the four subjects with diabetes mellitus showed improvement in glucose tolerance. Although minor side effects were uncommon, one patient died because of massive gastrointestinal haemorrhage from a duodenal ulcer.
Persistent Identifierhttp://hdl.handle.net/10722/161646
ISSN
2002 Impact Factor: 0.524
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorWang, Cen_US
dc.contributor.authorChan, Ven_US
dc.contributor.authorYeung, RTTen_US
dc.date.accessioned2012-09-05T05:13:28Z-
dc.date.available2012-09-05T05:13:28Z-
dc.date.issued1979en_US
dc.identifier.citationAustralian And New Zealand Journal Of Medicine, 1979, v. 9 n. 3, p. 225-232en_US
dc.identifier.issn0004-8291en_US
dc.identifier.urihttp://hdl.handle.net/10722/161646-
dc.description.abstractFive men and three women with active acromegaly were treated with bromocriptine. After three months' therapy (30 mg/day) mean GH during the day decreased by 50% in six out of eight subjects. In the remaining two subjects (non-responders) GH was persistently over 100 μg/l. Mean GH during glucose tolerance test were not significantly decreased in three out of the eight subjects, of whom two were the non-responders. The minimum dose of bromocriptine required to achieve maximum GH suppression ranged from 7.5 to 20 mg/day. In contrast, serum prolactin (PRL) throughout the day suppressed significantly in all subjects after 5 mg/day bromocriptine. Decreases in clinical symptoms, hand volume, urinary hydroxyproline and calcium excretion were seen in about half of the subjects. Three of the four subjects with diabetes mellitus showed improvement in glucose tolerance. Although minor side effects were uncommon, one patient died because of massive gastrointestinal haemorrhage from a duodenal ulcer.en_US
dc.languageengen_US
dc.publisherBlackwell Publishing Asia. The Journal's web site is located at http://www.blackwellpublishing.com/journals/IMJen_US
dc.relation.ispartofAustralian and New Zealand Journal of Medicineen_US
dc.subject.meshAcromegaly - Blood - Diagnosis - Drug Therapyen_US
dc.subject.meshAdulten_US
dc.subject.meshBlood Glucose - Analysisen_US
dc.subject.meshBromocriptine - Adverse Effects - Therapeutic Useen_US
dc.subject.meshDiabetes Complicationsen_US
dc.subject.meshDiabetes Mellitus - Diagnosisen_US
dc.subject.meshFemaleen_US
dc.subject.meshGlucose Tolerance Testen_US
dc.subject.meshGrowth Hormone - Blooden_US
dc.subject.meshHumansen_US
dc.subject.meshMaleen_US
dc.subject.meshMiddle Ageden_US
dc.subject.meshProlactin - Blooden_US
dc.titleTreatment of acromegaly with bromocriptineen_US
dc.typeArticleen_US
dc.identifier.emailChan, V:vnychana@hkucc.hku.hken_US
dc.identifier.authorityChan, V=rp00320en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1111/j.1445-5994.1979.tb04128.x-
dc.identifier.pmid288387-
dc.identifier.scopuseid_2-s2.0-0018645020en_US
dc.identifier.volume9en_US
dc.identifier.issue3en_US
dc.identifier.spage225en_US
dc.identifier.epage232en_US
dc.identifier.isiWOS:A1979HF61200002-
dc.publisher.placeAustraliaen_US
dc.identifier.scopusauthoridWang, C=7501631357en_US
dc.identifier.scopusauthoridChan, V=7202654865en_US
dc.identifier.scopusauthoridYeung, RTT=7102833337en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats